Mythili Sangem, MD

Mythili Sangem, MD, currently serves as the Head of Drug Safety, Pharmacovigilance and Risk Management at Apollomics, a position held since May 2021. Previously, Mythili was the Global Lead Medical Director for Drug Safety and Pharmacovigilance at FibroGen, Inc. from January 2016 to May 2021. Prior roles include Safety Physician in Drug Safety & Pharmacovigilance at Hyperion Therapeutics, Inc. (October 2014 - December 2015) and at Nektar Therapeutics (November 2011 - September 2014), as well as serving as a Consultant in Drug Safety & Pharmacovigilance at Ipsen from October 2010 to October 2011.